openPR Logo
Press release

Rare Neurodegenerative Disease Treatment Market Projected to Surpass US$ 119.2 Billion by 2033

07-10-2024 04:49 PM CET | Health & Medicine

Press release from: Fact.MR

Rare Neurodegenerative Disease Treatment Market Projected

The Rare neurodegenerative disease treatment market is poised to reach US $119.2 billion by the conclusion of 2033, with a projected compound annual growth rate (CAGR) of 5% throughout the forecast period. This market represents a pivotal and crucial aspect of the healthcare sector. Unlike more common ailments, rare neurodegenerative disorders affect a smaller population, presenting distinctive challenges in research and treatment development. Conditions such as Huntington's disease, ALS, and Niemann-Pick disease exact severe impacts on patients and their families, underscoring the urgent need for innovative therapies and compassionate care.

Advances in genetic research and diagnostic capabilities, which enable early and accurate illness detection, are driving growth in the rare neurodegenerative disease treatment market. The need for efficient therapies is also fueled by rising awareness of these disorders among the general public and medical experts. Moreover, pharmaceutical companies are encouraged to spend in research and development by regulatory incentives and orphan drug designations, which results in a more robust pipeline of medicines for these difficult-to-treat disorders.

Get Free Sample Copy of This Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=5197

Key Takeaways

The global market for treatments of rare neurodegenerative diseases is projected to reach US $72.9 billion in 2023, with an anticipated compound annual growth rate (CAGR) of 5% from 2023 to 2033. The United States is expected to dominate the market, driven by the introduction of novel treatment drugs and therapies, supported by its advanced healthcare infrastructure. This leadership position underscores ongoing efforts to address the complex challenges posed by rare neurodegenerative conditions like Huntington's disease and ALS. Meanwhile, Japan is poised for significant market growth, buoyed by its rapidly aging population, which is driving demand for effective therapies amidst increasing prevalence of neurodegenerative disorders in the elderly demographic. These trends highlight a global focus on advancing treatment options and enhancing quality of life for individuals affected by these challenging diseases.

Key Companies Profiled in This Report

Allergan Plc
GlaxoSmithKline Plc
Bayer AG
Teva Pharmaceuticals Industries Ltd.
Novartis AG
F. Hoffmann-La Roche Ltd.
Merck KGaA
Johnson & Johnson
Sanofi
Pfizer Inc.

Country-wise Insights

In the United States, the frequent introduction of new treatment drugs and therapies, alongside a well-established healthcare infrastructure, presents a highly opportunistic market environment for providers of rare neurodegenerative disease treatments. Key biopharmaceutical companies, extensive research activities, and increasing approvals for innovative treatment products further bolster market growth prospects. Additionally, heightened awareness about neurodegenerative disorder symptoms and a growing elderly population are set to drive sales of these treatments through 2033, emphasizing ongoing efforts to enhance therapeutic outcomes in conditions like ALS and Huntington's disease.

Similarly, Japan's aging population is a significant catalyst for the demand surge in rare neurodegenerative disease treatments throughout the forecast period. With elderly individuals at higher risk of such disorders, investments in research and the development of new neurological therapeutics are expected to intensify. The country's healthcare landscape benefits from increasing awareness of dementia, robust healthcare research focus, supportive governmental initiatives, and substantial investments in medical infrastructure. These factors collectively enhance the prospects for market expansion, with recent advancements such as stem cell research at Okayama University showcasing promising avenues for tackling diseases like ALS. In Europe, countries like Germany, France, and the United Kingdom are witnessing rising prevalence rates of neurodegenerative disorders, stimulating demand for advanced treatments. Continued investments in research and development, along with supportive governmental healthcare initiatives, are poised to further elevate the market for rare neurodegenerative disease treatments in these regions over the next decade.

Market Competition

Prominent providers of neurodegenerative disease therapy are consciously broadening their range of services to better cater to the distinct and changing requirements of patients and their families. This development is primarily motivated by the realisation that addressing the complex issues related to these diseases requires a holistic strategy. In order to offer complete assistance, leading providers of therapy for uncommon neurodegenerative diseases are embracing innovation and introducing new services and goods.

The renowned clinical services company Labcorp announced a big milestone in July 2022: the launch of its first blood test that can identify and confirm symptoms of many neurological diseases, such as dementia, ALS, and Parkinson's disease. This discovery is made possible by the tracking of a certain protein found in blood circulation called neurofilament light chain.

Want Full Report? Enquire Here-https://www.factmr.com/report/5197/rare-neurodegenerative-disease-treatment-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR:

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rare Neurodegenerative Disease Treatment Market Projected to Surpass US$ 119.2 Billion by 2033 here

News-ID: 3574994 • Views:

More Releases from Fact.MR

Pet Grooming Services Market Is Set To Cross US$ 6.7 Billion With A CAGR Of 7.2% By 2034
Pet Grooming Services Market Is Set To Cross US$ 6.7 Billion With A CAGR Of 7.2% …
The global pet grooming services market is experiencing remarkable growth and transformation, driven by increasing pet ownership, changing consumer attitudes towards pets, and rising disposable incomes. Valued at an estimated US$ 3.3 billion in 2024, the market is projected to reach a significant US$ 6.7 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.2%. This article delves into the factors contributing to this growth, the current trends
Halal Hair Care Market Is Expected to exceed US$ 1.07 billion by 2034
Halal Hair Care Market Is Expected to exceed US$ 1.07 billion by 2034
The global halal hair care market has been witnessing significant growth, reflecting the increasing demand for ethical and religiously compliant personal care products. As the market is projected to reach US$ 584.3 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 6.2% to exceed US$ 1.07 billion by 2034, it is essential to delve into the factors driving this growth, the challenges faced,
Liquid Packaging Carton Market is projected to reaching US$ 33.26 billion by 2034
Liquid Packaging Carton Market is projected to reaching US$ 33.26 billion by 203 …
The liquid packaging carton market, valued at a substantial US$ 18.93 billion in 2024, is projected to surge at a significant 5.8% CAGR, reaching an impressive US$ 33.26 billion by 2034. This robust growth trajectory underscores the increasing demand for sustainable packaging solutions and the rising consumer preference for convenient, eco-friendly packaging formats. In this comprehensive article, we will delve into the current trends, drivers, challenges, and future prospects of
Stock Cubes Market Is Predicted To Increase At A CAGR Of 4.8% During 2023 To 2033
07-12-2024 | Food & Beverage
Fact.MR
Stock Cubes Market Is Predicted To Increase At A CAGR Of 4.8% During 2023 To 203 …
The stock cubes market, standing at a valuation of US$ 7.35 billion in 2023, is an essential segment within the broader food industry. Stock cubes, also known as bouillon cubes, are concentrated flavors used to enhance the taste of soups, stews, sauces, and other dishes. They offer a convenient way for consumers to add depth and richness to their cooking without the need for long hours of preparation. As the

All 5 Releases


More Releases for ALS

ALS Contract Services joins J. Mallinson (Ormskirk) Ltd
J. Mallinson is extremely delighted to announce that following a period of extensive searching for a specialist strategic business partner, they have purchased ALS Contract Services from Agrovista, a leading supplier of agronomy advice, seed, crop protection products and precision farming services for an undisclosed fee. The acquisition will protect the long-term future of ALS and the business will provide a workforce of 35 in construction and sports pitch management
ALS Contract Services joins J. Mallinson (Ormskirk) Ltd
J. Mallinson is extremely delighted to announce that following a period of extensive searching for a specialist strategic business partner, they have purchased ALS Contract Services from Agrovista, a leading supplier of agronomy advice, seed, crop protection products and precision farming services for an undisclosed fee. The acquisition will protect the long-term future of ALS and the business will provide a workforce of 35 in construction and sports pitch management
Food Certification Market Future Growth Outlook | Intertek, BV, ALS
Latest survey on Food Certification Market is conducted to provide hidden gems performance analysis to better demonstrate competitive environment of Food Certification. The study is a mix of quantitative market stats and qualitative analytical information to uncover market size revenue breakdown by key business segments and end use applications. The report bridges the historical data from 2015 to 2020 and forecasted till 2026*, the outbreak of latest scenario in Food
ALS Treatment Market to Witness a Healthy CAGR of 19.21% by 2026 - ASURAGEN, INC …
Global ALS Treatment Market analysis report is also helpful in assessing the effectiveness of advertising programme and to know the causes of consumer resistance. The market report also contains the drivers and restraints for the ALS Treatment Market that are derived from SWOT analysis, and also shows what all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands that are driving the
Amyotrophic Lateral Sclerosis (ALS) Treatment Market : Trends And Growth
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time. According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate
Global Palladium Electrode Market 2018 - Metrohm, Murata, Kemet, ALS Co
The Global Palladium Electrode Market 2018 research report presents an in-depth research of the Global Palladium Electrode Sales Market alongside the Palladium Electrode market size and growth rate, classification of the Palladium Electrode industry based on products, and leading Palladium Electrode industry players as well. The Palladium Electrode industry report summarizes the global market insights that are key drivers for growth of the Palladium Electrode sales market over the forecast